Found, a telehealth platform focused on obesity treatment, will now offer weight-loss drugs Wegovy and Zepbound through newly available direct-to-consumer pharmacy programs from Novo Nordisk and Eli Lilly. Pricing starts at $499 per month for Wegovy and $349-$699 per vial for Zepbound.
Although the blockbuster weight-loss drugs may be in high demand, limited insurance coverage continues to leave many without access and priced out of treatment.
According to GoodRx, the number of people without commercial insurance coverage for Zepbound rose by more than 14% in 2025. For those who have insurance coverage, over 83% still have to meet additional requirements like prior authorization. And despite increased access to Wegovy in 2025, 83% of people with coverage still face hurdles like prior authorization or step therapy. Moreover, over 19 million people lack coverage for any GIP and GLP-1 agonists prescribed for weight loss.
“Since launching in 2019, we’ve recognized that effective weight care must be as unique as the individuals we serve,” Found CEO Luca Ranaldi said. “Our growing formulary addresses the reality that weight care is not one-size-fits-all. By offering multiple medication options and payment solutions, we’re building on our long-standing commitment to meet members where they are and provide care tailored to their unique biology, goals, and circumstances.”
